A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä

Non-Persistence With Antiplatelet Medications Among Older Patients With Peripheral Arterial Disease




TekijätWawruch Martin, Murin Jan, Tesar Tomas, Paduchova Martina, Petrova Miriam, Celovska Denisa, Havelkova Beata, Trnka Michal, Aarnio Emma

KustantajaFRONTIERS MEDIA SA

Julkaisuvuosi2021

Lehti: Frontiers in Pharmacology

Lehden akronyymiFRONT PHARMACOL

Artikkelin numeroARTN 687549

Vuosikerta12

Sivujen määrä9

ISSN1663-9812

eISSN1663-9812

DOIhttps://doi.org/10.3389/fphar.2021.687549

Verkko-osoitehttps://www.frontiersin.org/articles/10.3389/fphar.2021.687549/full

Rinnakkaistallenteen osoitehttps://research.utu.fi/converis/portal/detail/Publication/66438929


Tiivistelmä

Introduction: Antiplatelet therapy needs to be administered life-long in patients with peripheral arterial disease (PAD). Our study was aimed at 1) the analysis of non-persistence with antiplatelet medication in older PAD patients and 2) identification of patient- and medication-related characteristics associated with non-persistence.

Methods: The study data was retrieved from the database of the General Health Insurance Company. The study cohort of 9,178 patients aged >= 65 years and treated with antiplatelet medications was selected from 21,433 patients in whom PAD was newly diagnosed between 01/2012 and 12/2012. Patients with a 6 months treatment gap without antiplatelet medication prescription were classified as non-persistent. Characteristics associated with non-persistence were identified using the Cox regression.

Results: At the end of the 5 years follow-up, 3,032 (33.0%) patients were non-persistent. Age, history of ischemic stroke or myocardial infarction, clopidogrel or combination of aspirin with clopidogrel used at the index date, higher co-payment, general practitioner as index prescriber and higher overall number of medications were associated with persistence, whereas female sex, atrial fibrillation, anxiety disorders, bronchial asthma/chronic obstructive pulmonary disease, being a new antiplatelet medication user (therapy initiated in association with PAD diagnosis), and use of anticoagulants or antiarrhythmic agents were associated with non-persistence.

Conclusion: In patients with an increased probability of non-persistence, an increased attention should be paid to improvement of persistence.


Ladattava julkaisu

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.





Last updated on